Recent Funding Boost for ImmunOs Therapeutics AG
ImmunOs Therapeutics AG, an innovative biopharmaceutical company with its own immune system modulating HLA-based technology, has successfully closed a Series C financing round, raising $11 million. This funding will help advance the development of cutting-edge cancer therapies and strengthen relationships with its investors.
Collaboration with Key Investors
This funding round attracted support from important existing investors like Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners. Additionally, new investor Double Point Ventures joined in, signaling strong confidence in the company’s future prospects. Importantly, Steve Tregay, PhD, the Managing General Partner of Mission BioCapital, has joined ImmunOs’ Board of Directors, showing a strategic effort to improve governance and oversight.
Advancing Clinical Trials for IOS-1002
The funds from this financing effort will primarily be directed toward the active Phase Ia dose escalation clinical trials of ImmunOs' leading candidate, IOS-1002. This groundbreaking investigational therapy is being studied both as a standalone treatment and in combination with Merck's anti-PD-1 drug, KEYTRUDA (pembrolizumab), which highlights its potential in tackling advanced solid tumors using a diverse approach.
Significance of IOS-1002 in Cancer Treatment
IOS-1002 is an innovative, multifunctional immunotherapy designed to target various immune checkpoints, utilizing naturally occurring human leukocyte antigens (HLA) to promote a complex immune response. This new treatment aims to activate both innate and adaptive immune cells, which could transform the tumor microenvironment and improve the effectiveness of existing immuno-oncological therapies like KEYTRUDA. Such comparative treatments are crucial as the industry continues to advance.
Voices of Support from Key Players
Reinhard Ambros, the Executive Chairman of ImmunOs Therapeutics, shared his excitement about wrapping up this financing round. He highlighted the essential role of both current and new investors in affirming the company’s mission and future potential. “The funding enables us to move forward with our lead program, IOS-1002, as a groundbreaking therapy that addresses significant medical needs in cancer treatment,” he remarked. Other executives from participating firms echoed his enthusiasm, expressing their eagerness to be a part of ImmunOs Therapeutics' journey to improving cancer therapies.
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG is blazing a trail in biopharmaceutical innovation, focusing its research and development efforts on a unique immune system modulating technology platform. The company aims to develop first-in-class therapies that can effectively tackle cancer and autoimmune diseases. Its main program centers around a specialized HLA-fusion protein that interacts with selective receptors in the immune system, enhancing the body's ability to eliminate tumor cells and laying the groundwork for future advancements in personalized cancer therapies.
Company Contact Information
For more information about their groundbreaking work, you can reach out to ImmunOs Therapeutics AG at their headquarters in Schlieren, Switzerland. They are committed to advancing the clinical development of IOS-1002 and exploring its impressive potential to improve the lives of cancer patients.
Frequently Asked Questions
What recent funding has ImmunOs Therapeutics AG secured?
ImmunOs Therapeutics AG has raised $11 million through a Series C financing round to help support their clinical trials.
Who are the key investors involved in this funding round?
The funding round saw contributions from Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners, and new investor Double Point Ventures.
What is the focus of the IOS-1002 therapy?
IOS-1002 is an advanced immunotherapy aimed at treating solid tumors by targeting multiple immune checkpoints.
How does IOS-1002 work?
This therapy activates both innate and adaptive immune responses, potentially enhancing the effectiveness of current treatments like KEYTRUDA.
Where is ImmunOs Therapeutics AG located?
The company is based in Schlieren, Switzerland, where it focuses on developing innovative therapies for cancer and autoimmune diseases.
